(B) The Commissioner of Food and Drugs. 
(C) The Director of the Agency for 
Healthcare Research and Quality. 
(D) The Director of the Centers for Dis-
ease Control and Prevention. 
(E) The Director of the Indian Health 
Service. 
(F) The Director of the National Institutes 
of Health. 
(G) The Assistant Secretary of Defense for 
Health Affairs. 
(H) The Under Secretary for Health, De-
partment of Veterans Affairs. 
(3) APPOINTED
MEMBERS.—The members of 
the Consortium appointed by the Institute of Medi-
cine shall include the following: 
(A) Academics. 
(B) Practicing physicians. 
(C) Representatives of the following: 
(i) Hospitals. 
(ii) Drug companies. 
(iii) Device companies. 
(iv) Health care insurers, including 
State medicaid programs under title XIX
of the Social Security Act (42 U.S.C. 1396 
et seq.). 
(v) Employers or employer groups 
with a history of supporting health care 
quality initiatives. 
(vi) Patient advocacy groups. 
(vii) Professional societies. 
(viii) Health foundations. 
(4) MAJORITY
OF
MEMBERS.—A majority of 
the members of the Consortium shall be appointed 
by the Institute of Medicine under paragraph (3). 
(c) DUTIES.—The Consortium shall—
(1) establish research priorities under sub-
section (d); and 
(2) carry out section 205 (relating to standard-
ized measures of health care provider performance). 
(d) RESEARCH PRIORITIES.—
(1) ESTABLISHMENT.—On an annual basis, the 
Consortium shall establish priorities for research 
conducted 
or 
supported 
by 
the 
Agency 
for 
Healthcare Research and Quality under section 1013 
of the Medicare Prescription Drug, Improvement, 
and Modernization Act of 2003 (42 U.S.C. 299b–7) 
(relating to the effectiveness and efficiency of health 
care items and services).
(2) CONSIDERATION.—In establishing research 
priorities under subsection (c)(1), the Consortium 
shall take into consideration—
(A) the extent to which health care items 
and services—
(i) impact large numbers of people; or 
(ii) impose high health care costs; and 
(B) the extent of the need for data with re-
spect to diseases or conditions affected by those 
health care items and services. 
(3) TRANSPARENCY.—In carrying out this sec-
tion, the Consortium shall ensure that research pri-
orities are established in a manner that is publicly 
transparent. 
SEC. 203. CENTER FOR CLINICAL DECISION-SUPPORT 
TECHNOLOGY. 
(a) ESTABLISHMENT.—The Director, in collaboration 
with the National Library of Medicine, shall establish and 
support by grant or contract a Center for Clinical Deci-
sion-Support Technology to enable health care providers 
across the United States to more efficiently and rapidly 
embed knowledge-based elements in their clinical informa-
tion systems. 
(b) DUTIES.—The Center for Clinical Decision-Sup-
port Technology shall—
(1) design and develop new approaches to 
knowledge organization, modeling, and decision sup-
port; 
(2) develop standards and promote existing 
standards for guideline models, standard data sets, 
vocabularies, and interfaces among components of 
the decision-support system; 
(3) build tools to facilitate the encoding of med-
ical knowledge in a structured form to enable such 
knowledge to be used in patient-specific decision 
support, associated with other relevant evidence, up-
dated and maintained, and adapted to local systems 
and environments; 
(4) define and regularly update methods to de-
termine the effectiveness of such tools, including the 
appropriateness of the knowledge, the ease of adap-
tation to local environments, and the success of the 
intended application in achieving specific goals; 
(5) generalize or abstract the features of spe-
cific applications in the systems of the affiliated 
health care delivery organizations that have been 
found to be successful, but for which sharing and 
dissemination are not easily achieved, due to system-
specific designs; and